Frank Gentile, PhD, serves as Chief Operating Officer at Casma Therapeutics, which is pioneering novel therapeutic strategies to address unmet medical needs. He also serves as Entrepreneur-in-Residence at Third Rock Ventures, where he focuses on research and development opportunities. In addition, he serves as an adjunct professor of pharmacology and biotechnology in the division of biology and medicine at Brown University. Prior to joining Third Rock Ventures, Dr. Gentile served for 12 years as Senior Vice President, Research, Tekla Capital Management LLC, where he oversaw and executed biotechnology and healthcare investments in public and private companies in the areas of oncology, cardiovascular, infectious diseases, rare diseases, medical devices and diagnostics and discovery tools. Prior to Tekla, he was Vice President, Technology Program Management at Millennium Pharmaceuticals. Prior to joining Millennium, he was Vice President of Product Development at Curis, Inc., a biotechnology company in Cambridge developing products in the area of Regenerative Medicine. From 1997 to 2000 he was Director and then Vice President, Program Management at Reprogenesis, Inc. From 1990-1997 he was employed at CytoTherapeutics, Inc, where he held several scientific and management positions. Dr. Gentile received a B.E. degree in Chemical Engineering from The Cooper Union and a Ph.D. in Chemical Engineering from MIT. He has written over 120 peer reviewed publications and holds 30 US patents in the area of biotechnology.